Lixte Biotechnology Enters Material Definitive Agreement
Ticker: LIXT · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1335105
Sentiment: neutral
Topics: material-definitive-agreement
Related Tickers: LIXT
TL;DR
LIXT signed a big deal on 7/8. Details TBD.
AI Summary
Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on July 8, 2024. The filing does not specify the nature of the agreement or any associated dollar amounts.
Why It Matters
This filing indicates a significant new development or contract for Lixte Biotechnology, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its implications.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- July 8, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Lixte Biotechnology Holdings, Inc. enter into?
The filing states that Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on July 8, 2024, but does not specify the nature of the agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 8, 2024.
What is the principal executive office address for Lixte Biotechnology Holdings, Inc.?
The principal executive office address is 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
What is the telephone number for Lixte Biotechnology Holdings, Inc.?
The telephone number is (631) 830-7092.
What is the IRS Employer Identification Number for Lixte Biotechnology Holdings, Inc.?
The IRS Employer Identification Number is 20-2903526.
Filing Stats: 406 words · 2 min read · ~1 pages · Grade level 13.4 · Accepted 2024-07-12 16:05:21
Filing Documents
- form8-k.htm (8-K) — 33KB
- 0001493152-24-027085.txt ( ) — 241KB
- lixt-20240708.xsd (EX-101.SCH) — 3KB
- lixt-20240708_def.xml (EX-101.DEF) — 26KB
- lixt-20240708_lab.xml (EX-101.LAB) — 36KB
- lixt-20240708_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 12, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer